﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Kevin Sharer news stories on Newser</title><description>Read more Kevin Sharer stories on Newser</description><link>http://www.newser.com/taggrid/9489/kevin-sharer.html</link><image><url>http://img1-cdn.newser.com/images/newser-black250x40.gif</url><title>Kevin Sharer news stories on Newser</title><link>http://www.newser.com/</link></image><copyright>2012 - Newser</copyright><language>en-us</language><generator>Newser Feed Generator</generator><pubDate>Sat, 26 May 2012 11:44:38 CDT</pubDate><item><guid isPermaLink="true">http://www.newser.com/story/130145/how-ceo-pay-spirals-out-of-control.html</guid><title>How CEO Pay Spirals Out of Control</title><dc:creator>Kevin Spak</dc:creator><description>&lt;img src='http://img2-cdn.newser.com/getimage.aspx?mediaid=843823&amp;width=45&amp;height=45&amp;crop=Y&amp;updateddate=20111004125639' border='0' /&gt;Amgen didn’t do terribly well under CEO Kevin Sharer last year—it eliminated some 2,700 jobs and its stock fell 3%. Yet Sharer pocketed a 37% raise, bringing his compensation to $21 million. Why? Because the board decided he should be paid “closer to the 75th percentile of the...</description><media:content url="http://img2-cdn.newser.com/getimage.aspx?mediaid=843823&amp;width=45&amp;height=45&amp;crop=Y&amp;updateddate=20111004125639" type="image/jpg" medium="image"><media:description type="plain">In this file photograph taken April 21, 2010, the exterior view of Amgen Inc. offices is shown in Fremont, Calif.</media:description></media:content><link>http://www.newser.com/story/130145/how-ceo-pay-spirals-out-of-control.html</link><pubDate>Tue, 04 Oct 2011 12:56:18 CDT</pubDate></item><item><guid isPermaLink="true">http://www.newser.com/story/5916/biotech-giant-slashes-jobs.html</guid><title>Biotech Giant Slashes Jobs</title><dc:creator>Peter Fearon</dc:creator><description>&lt;img src='http://img2-cdn.newser.com/getimage.aspx?mediaid=19929&amp;width=45&amp;height=45&amp;crop=Y&amp;updateddate=20110401033120' border='0' /&gt;Biotech giant Amgen is slashing spending by $1.9 billion by cutting up to 14 percent of its workforce— 2,600 jobs—and closing some production facilities. The restructuring was triggered by plummeting sales of the company's anemia drug Aranesp. The shake up demonstrates that biotech operations are not immune...</description><media:content url="http://img2-cdn.newser.com/getimage.aspx?mediaid=19929&amp;width=45&amp;height=45&amp;crop=Y&amp;updateddate=20110401033120" type="image/jpg" medium="image" /><link>http://www.newser.com/story/5916/biotech-giant-slashes-jobs.html</link><pubDate>Thu, 16 Aug 2007 01:34:55 CDT</pubDate></item></channel></rss>
